OTC Growth Will Not Find A Friend In Europe’s Financial Upheaval
This article was originally published in The Tan Sheet
Executive Summary
As economic conditions tighten in Europe, former Pfizer exec Cavan Redmond expects consumers will spend less on OTCs while increasing their scrutiny of products and prices. Difficult economic conditions sharpen the constant necessity for OTC firms generate growth, he says.
You may also be interested in...
Pfizer’s Redmond Surfs To WebMD, With Consumer Health Future In Mind
Cavan Redmond left his role as Pfizer group president, with responsibility for consumer healthcare, to become CEO of the online health information provider May 31. The pharma veteran sees WebMD at the intersection of enabling consumers and physicians to make health care decisions.
Switch Obstacles In Europe Threaten OTC Industry Growth – GSK Exec
European perceptions that OTC status increases safety risks hinders switch applications, GSK exec Scarlett-Smith contends. He argues OTC buyers are health conscious, adverse events are not isolated to OTCs and despite the centralized switch process, members retain decentralized OTC policies.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.